RVMD
NASDAQ · Biotechnology
Revolution Medicines Inc
$205.15
+7.34 (+3.71%)
RVMD News2 articles
Tango Therapeutics Soars as Pancreatic Cancer Combo Shows 92% Response Rate
Tango Therapeutics shares rose sharply in premarket trading Monday after reporting a 92% objective response rate for its pancreatic cancer drug combo, with plans to move into Phase 3 testing.
Revolution Medicines Stock Gains Pre-Market on Promising Pancreatic Cancer Data
Revolution Medicines shares gained 1.9% premarket after Phase 3 data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months versus 6.7 months for chemotherapy.